NCT05814393 - To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

May 14, 2024

Study Completion Date

November 20, 2024

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Treatment Period(JW0201)

JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)

DRUG

Treatment Period(Placebo)

C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)

DRUG

Extension Period(JW0201)

JW0201: 200mg/day For 28 weeks(PO, BID) C2022: ≥1,000 mg/day for 28 Weeks(PO, BID) C2203: 25 mg/day for 28 Weeks(PO, BID)

Trial Locations (1)

Kangbuk Samsung Hospital, Seoul